TimesSquare Capital Management LLC Buys 144,516 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

TimesSquare Capital Management LLC raised its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 53.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 413,637 shares of the company's stock after buying an additional 144,516 shares during the quarter. TimesSquare Capital Management LLC owned 0.33% of Vaxcyte worth $33,860,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PCVX. Blue Trust Inc. increased its stake in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares during the period. Meeder Asset Management Inc. increased its stake in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after buying an additional 635 shares during the period. Nomura Asset Management Co. Ltd. acquired a new position in Vaxcyte in the 3rd quarter valued at approximately $92,000. Signaturefd LLC increased its stake in Vaxcyte by 51.9% in the 3rd quarter. Signaturefd LLC now owns 1,048 shares of the company's stock valued at $120,000 after buying an additional 358 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new position in Vaxcyte in the 4th quarter valued at approximately $161,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Transactions at Vaxcyte

In related news, SVP Mikhail Eydelman sold 5,000 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $91.49, for a total transaction of $457,450.00. Following the transaction, the senior vice president now owns 28,697 shares of the company's stock, valued at approximately $2,625,488.53. The trade was a 14.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total value of $670,800.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at $9,180,820.35. This represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 76,616 shares of company stock worth $6,766,481. Company insiders own 3.10% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on PCVX. Needham & Company LLC reissued a "buy" rating and issued a $14.00 target price on shares of Vaxcyte in a research report on Tuesday, February 11th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 target price for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $127.71.

Vaxcyte Trading Down 3.3 %

Vaxcyte stock traded down $2.73 on Friday, reaching $79.74. 1,252,550 shares of the stock were exchanged, compared to its average volume of 1,085,422. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06. The firm has a fifty day moving average price of $85.61 and a two-hundred day moving average price of $94.62. The stock has a market cap of $9.94 billion, a PE ratio of -17.33 and a beta of 0.98.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.